Cargando…

Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval

OBJECTIVES: Since population-based data on prognostic factors affecting survival in patients with breast cancer with bone metastasis (BM) are currently limited, we conducted this nationwide retrospective cohort study to examine the prognostic role of disease stage at breast cancer diagnosis and leng...

Descripción completa

Detalles Bibliográficos
Autores principales: Cetin, Karynsa, Christiansen, Christian Fynbo, Sværke, Claus, Jacobsen, Jacob Bonde, Sørensen, Henrik Toft
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420974/
https://www.ncbi.nlm.nih.gov/pubmed/25926150
http://dx.doi.org/10.1136/bmjopen-2015-007702
_version_ 1782369778782961664
author Cetin, Karynsa
Christiansen, Christian Fynbo
Sværke, Claus
Jacobsen, Jacob Bonde
Sørensen, Henrik Toft
author_facet Cetin, Karynsa
Christiansen, Christian Fynbo
Sværke, Claus
Jacobsen, Jacob Bonde
Sørensen, Henrik Toft
author_sort Cetin, Karynsa
collection PubMed
description OBJECTIVES: Since population-based data on prognostic factors affecting survival in patients with breast cancer with bone metastasis (BM) are currently limited, we conducted this nationwide retrospective cohort study to examine the prognostic role of disease stage at breast cancer diagnosis and length of BM-free interval (BMFI). SETTING: Denmark. PARTICIPANTS: 2427 women with a breast cancer diagnosis between 1997 and 2011 in the Danish Cancer Registry and a concurrent or subsequent BM diagnosis in the Danish National Registry of Patients. PRIMARY AND SECONDARY OUTCOME MEASURES: Survival (crude) based on Kaplan-Meier method and mortality risk (crude and adjusted for age, year of diagnosis, estrogen receptor status and comorbidity) based on Cox proportional hazards regression analyses by stage of disease at breast cancer diagnosis and by length of BMFI (time from breast cancer to BM diagnosis), following patients from BM diagnosis until death, emigration or until 31 December 2012, whichever came first. RESULTS: Survival decreased with more advanced stage of disease at the time of breast cancer diagnosis; risk of mortality during the first year following a BM diagnosis was over two times higher for those presenting with metastatic versus localised disease (adjusted HR=2.12 (95% CI 1.71 to 2.62)). With respect to length of BMFI, survival was highest in women with a BMFI <1 year (ie, in those who presented with BM at the time of breast cancer diagnosis or were diagnosed within 1 year). However, among patients with a BMFI ≥1 year, survival increased with longer BMFI (1-year survival: 39.9% (95% CI 36.3% to 43.6%) for BMFI 1 to <3 years and 52.6% (95% CI 47.4% to 57.6%) for BMFI ≥5 years). This pattern was also observed in multivariate analyses. CONCLUSIONS: Stage of disease at breast cancer diagnosis and length of BMFI appear to be important prognostic factors for survival following BM.
format Online
Article
Text
id pubmed-4420974
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44209742015-05-13 Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval Cetin, Karynsa Christiansen, Christian Fynbo Sværke, Claus Jacobsen, Jacob Bonde Sørensen, Henrik Toft BMJ Open Oncology OBJECTIVES: Since population-based data on prognostic factors affecting survival in patients with breast cancer with bone metastasis (BM) are currently limited, we conducted this nationwide retrospective cohort study to examine the prognostic role of disease stage at breast cancer diagnosis and length of BM-free interval (BMFI). SETTING: Denmark. PARTICIPANTS: 2427 women with a breast cancer diagnosis between 1997 and 2011 in the Danish Cancer Registry and a concurrent or subsequent BM diagnosis in the Danish National Registry of Patients. PRIMARY AND SECONDARY OUTCOME MEASURES: Survival (crude) based on Kaplan-Meier method and mortality risk (crude and adjusted for age, year of diagnosis, estrogen receptor status and comorbidity) based on Cox proportional hazards regression analyses by stage of disease at breast cancer diagnosis and by length of BMFI (time from breast cancer to BM diagnosis), following patients from BM diagnosis until death, emigration or until 31 December 2012, whichever came first. RESULTS: Survival decreased with more advanced stage of disease at the time of breast cancer diagnosis; risk of mortality during the first year following a BM diagnosis was over two times higher for those presenting with metastatic versus localised disease (adjusted HR=2.12 (95% CI 1.71 to 2.62)). With respect to length of BMFI, survival was highest in women with a BMFI <1 year (ie, in those who presented with BM at the time of breast cancer diagnosis or were diagnosed within 1 year). However, among patients with a BMFI ≥1 year, survival increased with longer BMFI (1-year survival: 39.9% (95% CI 36.3% to 43.6%) for BMFI 1 to <3 years and 52.6% (95% CI 47.4% to 57.6%) for BMFI ≥5 years). This pattern was also observed in multivariate analyses. CONCLUSIONS: Stage of disease at breast cancer diagnosis and length of BMFI appear to be important prognostic factors for survival following BM. BMJ Publishing Group 2015-04-29 /pmc/articles/PMC4420974/ /pubmed/25926150 http://dx.doi.org/10.1136/bmjopen-2015-007702 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Oncology
Cetin, Karynsa
Christiansen, Christian Fynbo
Sværke, Claus
Jacobsen, Jacob Bonde
Sørensen, Henrik Toft
Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
title Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
title_full Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
title_fullStr Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
title_full_unstemmed Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
title_short Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
title_sort survival in patients with breast cancer with bone metastasis: a danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420974/
https://www.ncbi.nlm.nih.gov/pubmed/25926150
http://dx.doi.org/10.1136/bmjopen-2015-007702
work_keys_str_mv AT cetinkarynsa survivalinpatientswithbreastcancerwithbonemetastasisadanishpopulationbasedcohortstudyontheprognosticimpactofinitialstageofdiseaseatbreastcancerdiagnosisandlengthofthebonemetastasisfreeinterval
AT christiansenchristianfynbo survivalinpatientswithbreastcancerwithbonemetastasisadanishpopulationbasedcohortstudyontheprognosticimpactofinitialstageofdiseaseatbreastcancerdiagnosisandlengthofthebonemetastasisfreeinterval
AT sværkeclaus survivalinpatientswithbreastcancerwithbonemetastasisadanishpopulationbasedcohortstudyontheprognosticimpactofinitialstageofdiseaseatbreastcancerdiagnosisandlengthofthebonemetastasisfreeinterval
AT jacobsenjacobbonde survivalinpatientswithbreastcancerwithbonemetastasisadanishpopulationbasedcohortstudyontheprognosticimpactofinitialstageofdiseaseatbreastcancerdiagnosisandlengthofthebonemetastasisfreeinterval
AT sørensenhenriktoft survivalinpatientswithbreastcancerwithbonemetastasisadanishpopulationbasedcohortstudyontheprognosticimpactofinitialstageofdiseaseatbreastcancerdiagnosisandlengthofthebonemetastasisfreeinterval